Q-omics provides the consensus-scored LRIG2-DT profile across patient tissues and cancer cell-line models. LRIG2-DT expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LRIG2-DT is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, LRIG2-DT RNA expression shows 19,204 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, THCA, and UVM as cancer lineages where LRIG2-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRIG2-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRIG2-DT survival associations across molecular data types. LRIG2-DT RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRIG2-DT RNA expression–survival associations across cancer types. High LRIG2-DT expression shows unfavorable associations in UCEC, LAML, KIRC and KIRP, but favorable associations in BRCA and LGG. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for LRIG2-DT RNA expression.
This table summarizes LRIG2-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LRIG2-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRIG2-DT shows lower tumor expression in THCA, UCEC, BLCA, LUSC, BRCA and KICH. The THCA box plot shows higher LRIG2-DT RNA expression in normal versus tumor tissue (log2 FC = −0.769, t-test p < 0.001).
This table shows molecular features associated with LRIG2-DT in patient tissues and cancer cell lines. In patient samples, LRIG2-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
